#USA #Philadelphia #CAR T Therapy #Verismo Therapeutics #SynKIR-310

Verismo Therapeutics Presents Novel Preclinical Data on SynKIR™-310

Verismo Therapeutics, a pioneering clinical-stage company in CAR T technology, unveiled promising new preclinical data for their innovative KIR-CAR therapy, SynKIR™-310, during the American Society of Hematology (ASH) Annual Meeting in 2025. This novel therapy is specifically designed to target CD19, a common marker in B cell malignancies, and is part of a new wave of CAR T treatments that aim to enhance efficacy while minimizing side effects.

Key Findings

In the latest studies, SynKIR™-310 showed significantly improved outcomes compared to the traditional CD19-targeting CAR T therapies, particularly those analogous to the well-known tisagenlecleucel. Dr. Megan Blair of Verismo showcased the following highlights:

1. Faster Tumor Regression: The KIR-CAR technology demonstrated a quicker reduction in tumor size and a more efficient clearance of B cell tumors in immunocompromised NSG mice. Remarkably, low doses of SynKIR™-310 were able to outperform higher doses of conventional CAR T cells, indicating the potential for effective treatment with fewer resources.

2. Mechanism of Action: One of the critical insights from the data is the enhanced anti-tumor activity attributed solely to the novel KIR-CAR signaling pathway. This finding suggests that the effectiveness of SynKIR™-310 does not rely on CD19 binding, contrasting with the limitations of conventional therapies.

3. Reduced Cytokine Release: In vivo studies revealed that SynKIR™-310 triggered less cytokine release compared to traditional CAR T cells, suggesting a lower risk for cytokine release syndrome – a common and often severe side effect seen in CAR T therapies. This reduction is crucial as it may help minimize toxicity while maintaining robust anti-tumor effects.

Implications for Cancer Treatment

“The current upper limit of CD19 CAR T therapies has set a new bar in treating B-cell malignancies; however, the collateral damage caused by cytokine release syndrome remains a notable concern,” said Dr. Laura Johnson, Chief Science Officer at Verismo. “Our findings support that SynKIR™-310's innovative KIR-CAR design promotes not only a stronger and faster tumor response but does so with a potentially lower risk of adverse effects, particularly for patients grappling with relapsed or refractory B cell cancers.”

SynKIR™-310 is currently under evaluation in a Phase 1 clinical trial (NCT06544265) aimed at adult patients with relapsed or refractory non-Hodgkin lymphoma. This emerging therapy represents Verismo’s commitment to revolutionizing treatment paradigms in hematological malignancies.

About Verismo Therapeutics

Verismo Therapeutics, leveraging its proprietary KIR-CAR technology, is at the forefront of developing advanced CAR T cell therapies. Their unique platform utilizes a bifunctional signaling approach to improve the efficacy of T cell responses, and minimize exhaustion, particularly in severe cases of B-cell malignancies and solid tumors. Verismo continues to make strides with other assets in their pipeline, including SynKIR™-110, thereby positioning itself as a leader in the fight against cancer.

For more information on Verismo Therapeutics and their groundbreaking research, visit Verismo Therapeutics.